Assignment 1: Prescribing for Children and Adolescents

profileyemisij

PLEASE FOLLOW INSTRUCTION BELOW

ZERO PLAGIARISM/FIVE REFERENCES  NOT MORE THAN FIVE YEARS

FOLLOW 7TH APA WRITING FORMAT

WEEK 3 ASSIGNMENT TOPIC  GIVEN TO ME TO ADDRESS IS MAJOR DEPRESSIVE DISORDER.

Off-label prescribing is when a physician gives you a drug that the U.S. Food and Drug Administration (FDA) has approved to treat a condition different than your condition. This practice is legal and common. In fact, one in five prescriptions written today are for off-label use.

—Agency for Healthcare Research and Quality

 

Psychotropic drugs are commonly used for children and adolescents to treat mental health disorders, yet many of these drugs are not FDA approved for use in these populations. Thus, their use is considered “off-label,” and it is often up to the best judgment of the prescribing clinician. As a PMHNP, you will need to apply the best available information and research on pharmacological treatments for children in order to safely and effectively treat child and adolescent patients. Sometimes this will come in the form of formal studies and approvals for drugs in children. Other times you may need to extrapolate from research or treatment guidelines on drugs in adults. Each individual patient case will need to be considered independently and each treatment considered from a risk assessment standpoint. What psychotherapeutic approach might be indicated as an initial treatment? What are the potential side effects of a particular drug?

For this Assignment, you consider these questions and others as you explore FDA-approved (“on label”) pharmacological treatments, non-FDA-approved (“off-label”) pharmacological treatments, and nonpharmacological treatments for disorders in children and adolescents.

  • 2 years ago
  • 40
Answer(1)

Purchase the answer to view it

blurred-text
  • attachment
    PrescribingforChildrenandAdolescents.docx
  • attachment
    PrescribingforChildrenandAdolescents.pdf
  • attachment
    icp-35-137.pdf
  • attachment
    1-s2.0-S2215036616303789-main.pdf
  • attachment
    s41380-019-0574-2.pdf
  • attachment
    ohtas-19-1.pdf
  • attachment
    appi.focus.16407.pdf